The Potential of Gene Transfer into Primary B-CLL Cells Using Recombinant Virus Vectors

References

• Keating, M.J. (1999) "Chronic lymphocytic leukemia", Semin. OncoL, 26, 107–114.
   Google Scholar
• Wendtner, C.-M., Schmitt, B., Bergmann, M., Röhnisch, T., Buhmann, R. and Hallek, M. (2001) "New aspects on the pathogenesis, diagnostic procedures and therapeutic management of chronic lymphocytic leukemia", Int. J. HematoL, 73, 32— 38.
   Google Scholar
• Schetelig, J., Thiede, C., Bornhauser, M., Schwerdtfeger, R., Kiehl, M., Beyer, J., et al. (2003) "Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Coopera-tive German Transplant Study Group", J. Clin. OncoL, 21, 2747 — 2753.
   Web of Science ®Google Scholar
• Vuillier, F. and Dighiero, G. (2003) "Monocyte-derived dendritic cells in chronic lymphocytic leukemia", Leuk. Lymphoma, 44, 1267–1273.
   PubMed Web of Science ®Google Scholar
• Ranheim, E.A. and Kipps, T.J. (1993) "Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal", J. Exp. Med., 177, 925–935.
   PubMed Web of Science ®Google Scholar
• Cantwell, M.J., Hua, T., Pappas, J. and Kipps, T.J. (1997) "Acquired CD40-ligand deficiency in chronic lymphocytic leuke-mia", Nature Med., 3, 984–989.
   PubMed Web of Science ®Google Scholar
• Kato, K., Cantwell, M.J., Sharma, S. and Kipps, T.J. (1998) "Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells", J. Clin. Invest., 101, 1131 — 1141.
   Google Scholar
• Wierda, G., Cantwell, M.J., Woods, Si., Rassenti, L.Z., Prussak, C.E. and Kipps, T.J. (2000) "CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia", Blood, 96, 2917— 2924.
   Google Scholar
• Buschle, M., Brenner, M.K., Chen, IS., Drexler, H.G., Gignac, S.M. and Rooney, C.M. (1990) "Transfection and gene expression in normal and malignant primary B lymphocytes", J. ImmunoL Methods, 133, 77–85.
   PubMed Web of Science ®Google Scholar
• Huang, M.R., Olsson, M., Kallin, A., Pettersson, U. and Totter-man, T.H. (1997) "Efficient adenovirus-mediated gene transduction of normal and leukemic hematopoietic cells", Gene Ther., 4, 1093 — 1099.
   Google Scholar
• Cantwell, M.J., Sharma, S., Friedmann, T. and Kipps, T.J. (1996) "Adenovirus vector infection of chronic lymphocytic leukemia B cells", Blood, 88, 4676–4683.
   Google Scholar
• Wattel, E., Vanrumbeke, M., Abina, M.A., Cambier, N., Pre-udhomme, C., Haddada, H., et al. (1996) "Differential efficacy of adenoviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies", Leukemia, 10, 171 — 174.
   Google Scholar
• Takahashi, S., Rousseau, R.F., Yotnda, P., Mei, Z., Dotti, G., Rill, D., et al. (2001) "Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes", Hum. Gene Ther., 12, 659–670.
   Web of Science ®Google Scholar
• Yang, R., Nunes, F.A. and Berencsi, K. (1994) "Cellular immunity to vital antigens limits El-deleted adenoviruses for gene therapy", Proc. Natl. Acad. Sci. USA, 91, 4407–4411.
   PubMed Web of Science ®Google Scholar
• Chu, P., Deforce, D., Pedersen, I.M., Kim, Y., Kitada, S., Reed, J.C., et al. (2002) "Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia", Proc. Natl. Acad. Sci. USA, 99, 3854— 3859.
   PubMed Web of Science ®Google Scholar
• Battle, T.E., Wierda, W.G., Rassenti, L.Z., Zahrieh, D., Neuberg, D., Kipps, T.J., et al. (2003) "In vivo activation of signal transducer and activator of transcription factor 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response", Clin. Cancer Res., 9, 2166 — 2172.
   Web of Science ®Google Scholar
• Anether, G., Marschitz, I., Tinhofer, I. and Greil, R. (2002) "Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia", Blood, 99, 722–723.
   PubMed Web of Science ®Google Scholar
• Monahan, P.E. and Samulski, R.J. (2000) "AAV vectors: Is clinical success on the horizon?", Gene Ther., 7, 24— 30.
   Google Scholar
• Maass, G., Bogedain, C., Scheer, U., Michl, D., Wirer, M., Braun-Falco, M., et al. (1998) "Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells", Hum. Gene Ther., 9, 1049–1059.
   PubMed Web of Science ®Google Scholar
• Kay, M.A., Manno, CS., Ragni, M.V., Larson, P.J., Couto, L.B., McClelland, A., et al. (2000) "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector", Nat. Genet., 24, 257 — 261.
   PubMed Web of Science ®Google Scholar
• Wagner, J.A., Nepomuceno, TB., Messner, A.H., Moran, M.L, Batson, E.P., Dimiceli, S., et al. (2002) "A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies", Hum. Gene Ther., 13, 1349— 1359.
   Web of Science ®Google Scholar
• Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., et al. (2002) "Gene therapy of Canavan disease : AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain", Hum. Gene Ther., 13, 1391–1412.
   Web of Science ®Google Scholar
• Rohr, UP., Kronenwetter, R. and Haas, R. (1999) "Transduction efficiencies of primary normal and malignant cells using a recombinant AAV-2 vector depend on cell type and cell cycle", Blood, 94, 181a (abstract).
   Google Scholar
• Xiao, X., Li, J. and Samulski, R.J. (1998) "Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus", J. Virol., 72, 2224–2232.
   PubMed Web of Science ®Google Scholar
• Grimm, D., Kern, A., Rittner, K. and Kleinschmidt, J.A. (1998) "Novel tools for production and purification of recombinant adeno-associated virus vectors", Hum. Gene Ther., 9, 2745–2760.
   Web of Science ®Google Scholar
• Hermens, W.T.J.M.C., Brake, O.T., Dfikhuizen, P.A., Sonnemans, M.A., Grimm, D., Kleinschmidt, J.A., et al. (1999) "Purification of recombinant adeno-associated virus by iodixanol gradient ultra-centrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system", Hum. Gene Ther., 10, 1885 — 1891.
   Web of Science ®Google Scholar
• Seisenberger, G., Ried, M.U., Endress, T., Bfining, H., Hallek, M. and Brduchle, C. (2001) "Real-time single-molecule imaging of the infection pathway of an adeno-associated virus", Science, 294, 1929 — 1932.
   Web of Science ®Google Scholar
• Wendtner, C.-M., Kofler, D.M., Theiss, H.D., Kurzeder, C., Buhmann, R., Schweighofer, C., et al. (2002) "Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombi-nant adeno-associated virus (rAAV) vectors", Blood, 100, 1655 — 1661.
   Google Scholar
• Buhmann, R., Nolte, A., Westhaus, D., Emmerich, B. and Hallek, M. (1999) "CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells", Blood, 93, 1992–2002.
   Google Scholar
• Decker, T., Schneller, F., Sparwasser, T., Tretter, T., Lipford, G.B., Wagner, H., et al. (2000) "Immunostimulatory CpG-oligonucleo-tides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells", Blood, 95, 999–1006.
   Google Scholar
• Theiss, H.D., Kofler, D.M., Bfining, H., Aldenhoff, A., Kaess, B., Decker, T., et al. (2003) "Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-CLL cells by CpG-oligodeoxynucleotides", Exp. HematoL, 31, 1223–1229.
   Web of Science ®Google Scholar
• Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., et al. (2002) "Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity", J. Virol., 76, 791–801.
   PubMed Web of Science ®Google Scholar
• Mining, H., Ried, MU., Perabo, L., Gerner, F.M., Huttner, N.A., Enssle, J., et al. (2003) "Receptor targeting of adeno-associated virus vectors", Gene Ther., 10, 1142–1151.
   PubMed Web of Science ®Google Scholar
• Grifman, M., Trepel, M., Speece, P., Gilbert, L.B., Arap, W., Pasqualini, R., et al. (2001) "Incorporation of tumor —targeting peptides into recombinant adeno-associated virus capsids", MoL Ther., 3, 964–975.
   PubMed Web of Science ®Google Scholar
• Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., et al. (2001) "Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells", MoL Ther., 4, 174–181.
   PubMed Web of Science ®Google Scholar
• Shi, W., Arnold, G.S. and Bartlett, J.S. (2001) "Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors", Hum. Gene Ther., 12, 1697–1711.
   Web of Science ®Google Scholar
• Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., et al. (2000) "Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism", J. Virol., 74, 8635–8647.
   PubMed Web of Science ®Google Scholar
• Girod, A., Pied, M., Wobus, C., Lahm, M., Leike, K., Kleinsch-midt, J., et al. (1999) "Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2", Nat. Med., 5, 1052 — 1056.
   Google Scholar
• Pied, M.U., Girod, A., Leike, K., Mining, H. and Hallek, M. (2002) "Adeno-associated virus capsids displaying immunoglobulin-bind-ing domains permit antibody-mediated vector retargeting to specific cell surface receptors", J. Virol., 76, 4559–4566.
   PubMed Web of Science ®Google Scholar
• Perabo, L, BUning, H, Kofler, D.M., Pied, M.U., Girod, A., Wendtner, C.-M., et al. (2003) "In vitro selection of viral vectors with modified tropism: the adeno-associated virus display", Mol. Ther., 8, 151–157.
   PubMed Web of Science ®Google Scholar
• Tatsumi, E., Harada, S., Bechtold, T., Lipscomb, H., Davis, J., Kuszynski, C., et al. (1986) "In-vitro infection of chronic lymphocytic leukemia cells by Epstein-Barr virus (EBV)", Leuk. Res., 10, 167 — 177.
   Google Scholar
• Walls, E.V., Doyle, M.G., Patel, K.K., Allday, M.J., Catovsky, D. and Crawford, D.H. (1989) "Activation and immortalization of leukemic B cells by Epstein-Barr virus", Int. J. Cancer, 44,846–853.
   PubMed Web of Science ®Google Scholar
• Doyle, M.G., Catovsky, D. and Crawford, D.H. (1993) "Infection of leukemic B lymphocytes by Epstein Barr virus", Leukemia, 7, 1858 — 1864.
   Google Scholar
• Avila-Carino, J., Lewin, N., Yamamoto, K., Tomita, Y., Mellstedt, H., Brodin, B., et al. (1994) "EBV infection of B-CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype", Int. J. Cancer, 58, 678–685.
   Web of Science ®Google Scholar
• Rickinson, A., Finerty, S. and Epstein, M. (1982) "Interaction of Epstein-Barr virus with leukemic B cells in vitro. Abortive infection and rare cell line establishment from chronic lymphocytic leukemic cells", Clin. Exp. Immunol., 50, 347 — 354.
   PubMed Web of Science ®Google Scholar
• Laytragoon-Lewin, N., Chen, F., Avila-Carino, J., Zou, J.Z., Mellstedt, H., Ernberg, I., et al. (1995) "Epstein Barr virus (EBV)-carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPs but not EBNA2 in vivo", Int. J. Cancer, 63, 486–490.
   Web of Science ®Google Scholar
• Hammerschmidt, W. and Sugden, B. (1989) "Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes", Nature, 340, 393— 397.
   Google Scholar
• Banerjee, S., Livanos, E. and Vos, J.M.H. (1995) "Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus", Nature Med., 12, 1303— 1308.
   Google Scholar
• Kempkes, B., Pich, D., Zeidler, R., Sugden, B. and Hammer-schmidt, W. (1995) "Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA", J. Virol., 69, 231 — 238.
   PubMed Web of Science ®Google Scholar
• Kilger, E., Pecher, G., Schwenk, A. and Hammerschmidt, W. (1999) "Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells", J. Gene Med., 1, 84–92.
   PubMed Web of Science ®Google Scholar
• Hammerschmidt, W. and Sugden, B. (1998) "Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus", Cell, 55, 427–433.
   Google Scholar
• Zimmermann, J. and Hammerschmidt, W. (1995) "Structure and role of the terminal repeats of Epstein-Barr virus in processing and packaging of virion DNA", J. Virol., 69, 3147–3155.
   PubMed Web of Science ®Google Scholar
• Delecluse, H.J., Pich, D., Hilsendegen, T., Baum, C. and Hammerschmidt, W. (1999) "A first-generation packaging cell line for Epstein-Barr virus-derived vectors", Proc. Natl. Acad. Sci. USA, 96, 5188 — 5193.
   PubMed Web of Science ®Google Scholar
• Delecluse, H.J., Hilsendegen, T., Pich, D., Zeidler, R. and Hammerschmidt, W. (1998) "Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells", Proc. Natl. Acad. Sci. USA, 95, 8245–8250.
   PubMed Web of Science ®Google Scholar
• Schepers, A., Pich, D. and Hammerschmidt, W. (1993) "A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus", EMBO J., 12, 3921–3929.
   PubMed Web of Science ®Google Scholar
• Wendtner, C.-M., Kurzeder, C., Theiss, H.D., Kofler, D.M., Baumert, J., Delecluse, Hi., et al. (2003) "High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectors", Exp. Hematol., 31, 99 — 108.
   Google Scholar
• Russell, D.W., Miller, A.D. and Alexander, I.E. (1995) "Adeno-associated virus vectors preferentially transduce cells in S phase", Proc. Natl. Acad. Sci. USA, 91, 8915–8919.
   Web of Science ®Google Scholar
• Cohen, J.I., Wang, F., Mannick, J. and Kieff, E. (1989) "Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation", Proc. Natl. Acad. Sci. USA, 86, 9558–9562.
   PubMed Web of Science ®Google Scholar
• Tomkinson, B., Robertson, E. and Kieff, E. (1993) "Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation", J. Virol., 67, 2014–2025.
   Google Scholar
• Kaye, K.M., Izumi, K.M. and Kieff, E. (1993) "Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation", Proc. Natl. Acad. Sci. USA, 90, 9150–9154.
   PubMed Web of Science ®Google Scholar
• Jones, J.F., Shurin, S., Abramowsky, C., Tubbs, R.R., Sciotto, C.G., Wahl, R., etal. (1988) "T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infection", N. Engl. J. Med., 318, 733–738.
   PubMed Web of Science ®Google Scholar
• Young, L., Alfieri, C., Hennessy, K., Evans, H., O'Hara, C., Anderson, K.C., et al. (1989) "Expression of Epstein Barr virus transformation associated genes in tissues of patients with EBV lymphoproliferative disease", N. EngL J. Med., 321, 1080 — 1085.
   Google Scholar
• Lee, ES., Locker, J.L., Nalesnik, M., Reyes, J., Jaffe, R., Alashari, M., et al. (1995) "The association of Epstein-Barr virus with smooth-muscle tumors occuring after organ transplantation", N. Engl. J. Med., 332, 19–25.
   Google Scholar
• Tao, Q., Robertson, K.D., Manns, A., Hildesheim, A. and Ambinder, R.F. (1998) "Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue", Blood, 91, 1373–1381.
   Google Scholar
• Baumforth, KR., Young, L.S., Favell, K.J., Constandinou, C. and Murray, P.G. (1999) "The Epstein-Barr virus and its association with human cancers", MoL Pathol., 52, 307 — 322.
   Google Scholar
• Glorioso, J.C., DeLuca N.A. and Fink, D.J. (1995) "Development and application of herpes simplex virus vectors for human gene therapy", Ann. Rev. Microbiol., 49, 675–710.
   PubMed Web of Science ®Google Scholar
• Sena-Esteves, M., Saeki, Y., Fraefel, C. and Breakefield, X.O. (2000) "HSV-1 amplicon vectors — simplicity and versatility", Mol. Ther., 2, 9 —15.
   Google Scholar
• Frenkel, N., Singer, O. and Kwong, A.D. (1994) "Minireview: the herpes simplex virus amplicon - a versatile defective virus vector", Gene Ther., 1\(suppl 1), S40–546.
   PubMedGoogle Scholar
• Eling, D.J., Johnson, P.A., Sharma, S., Tufaro, F. and Kipps, T.J. (2000) "Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A", Gene Ther., 7, 1210–1216.
   PubMed Web of Science ®Google Scholar
• Misumi, M., Suzuki, T., Moriuchi, S., Glorioso, J.C. and Bessho, M. (2003) "In vitro thymidine kinase/ganciclovir-based suicide gene therapy using replication detective herpes simplex virus-1 against leukemic B-cell malignancies (MCL, HCL, B-CLL)", Leuk. Res., 27, 695–699.
   Google Scholar
• Spaete, R.R. and Frenkel, N. (1982) "The herpes simplex virus amplicon: a new eukaryotic defective-virus cloning-amplifying vector", Cell, 30, 295–304.
   Google Scholar
• Fraefel, C., Song, S., Lim, F., Lang, P., Yu, L., Wang, Y., et al. (1996) "Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells", J. Virol., 70, 7190–7197.
   PubMed Web of Science ®Google Scholar
• Saeki, Y., Ichikawa, T., Saeki, A., Chiocca, E.A., Tobler, K., Ackermann, M., et al. (1998) "Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors", Hum. Gene Ther., 9, 2787 — 2794.
   Web of Science ®Google Scholar
• Tolba, K.A., Bowers, W.J., Hilchey, S.P., Haltermann, MW., Howard, D.F., Giuliano, RE., etal. (2001) "Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lym-phocytic leukemia", Blood, 98, 287 — 295.
   Google Scholar
• Hill, A., Jugovic, P., York, I., Russ, G., Bennink, J., Yewdell, J., et al. (1995) "Herpes simplex virus turns off the TAP to evade host immunity", Nature, 375, 411 — 415.
   Google Scholar
• Fruh, K., Ahn, K., Djaballah, H., Sempe, P., van Endert, P.M., Tampe, R., et al. (1995) "A viral inhibitor of peptide transporters for antigen presentation", Nature, 375, 415–418.
   Google Scholar
• Tolba, K.A., Bowers, W.J., Eling, D.J., Casey, A.E., Kipps, Federoff, Hi., et al. (2002) "HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia", Mol. Ther., 6, 455–46.
   PubMed Web of Science ®Google Scholar
• Hammerschmidt, W. (2000) "Herpesvirus vectors come of age", Curr. Opin. Mol. Ther., 2, 532–539.
   PubMed Web of Science ®Google Scholar
• Overell, R.W., Weisser, K.E., Hess, B.W., Ziegler, S.F., Pleiman, C.M., Maliszewski, C., et al. (1991) "Efficient gene transfer and expression in primary B lymphocytes", J. Immunol. Methods, 141, 53–62.
   PubMed Web of Science ®Google Scholar
• Ballantyne, J., Henry, D.L., Muller, JR., Briere, F., Snapper, C.M., Kehry, M., et al. (1998) "Efficient recombination of a switch substrate retrovector in CD40-activated B lymphocytes: implica-tions for the control of CH gene switch recombination", J. Immunol., 161, 1336–1347.
   PubMed Web of Science ®Google Scholar
• Jaleco, A.C., Stegmann, A.P., Heemskerk, M.H., Couwenberg, F., Bakker, A.Q., Weijer, K., et al. (1999) "Genetic modification of human B-cell development: B-cell development is inhibited by the dominant negative helix-loop helix factor Id3", Blood, 94, 2637 — 2647.
   Google Scholar
• Miller, D.G., Adam, M.A. and Miller, A.D. (1990) "Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection", Mol. Cell Biol., 10, 4239–4242.
   Web of Science ®Google Scholar
• Bovia, F., Salmon, P., Matthes, T., Kvell, K., Nguyen, T.H., Werner-Favre, C., et al. (2003) "Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors", Blood, 101, 1727–1733.
   PubMed Web of Science ®Google Scholar
• Woods, N.-B., Fahlman, C., Mikkola, H., Hamaguchi, I., Olsson, K., Zufferey, R., et al. (2000) "Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells", Blood, 96, 3725 — 3733.
   Google Scholar
• Chinnasamy, D., Chinnasamy, N., Enriquez, M.J., Otsu, M., Morgan, R. and Canditti, F. (2000) "Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins", Blood, 96, 1309–1316.
   PubMed Web of Science ®Google Scholar
• Salmon, P., Kindler, V., Ducrey, O., Chapuis, B., Zubler, R.H. and Trono, D. (2000) "High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors", Blood, 96, 3392 — 3398.
   Google Scholar
• Zack, JA., Arrigo, Si., Weitsman, SR., Go, AS., Haislip, A. and Chen, I.S. (1990) "HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile latent viral structure", Cell, 61, 213— 222.
   Google Scholar
• Ducrey-Rundquist, O., Guyader, M. and Trono, D. (2002) "Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes", J. Virol., 76, 9103 —9111.
   PubMed Web of Science ®Google Scholar
• Stripecke, R., Cardoso, A.A., Pepper, K.A., Skelton, D.C., Yu, Mascarenhas, L., et al. (2000) "Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage-colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses", Blood, 96, 1317 — 1326.
   Google Scholar
• Vonderheide, R.H., Hahn, W.C., Schultze, J.L. and Nadler, L.M. (1999) "The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes", Immunity, 10, 673–679.
   Google Scholar
• Trojan, A., Schultze, J.L., Witzens, M., Vonderheide, R.H., Ladetto, M., Donovan, J.W., et al. (2000) "Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies", Nat. Med., 6, 667 — 672.
   Web of Science ®Google Scholar
• Jager, E., Gnjatic, S., Nagata, Y., Stockert, E., Jager, D., Karbach, J., et al. (2000) "Induction of primary NY-ESO-1 immunity: CD8 + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 + cancers", Proc. Natl. Acad. Sci. USA, 97, 12198 — 12203.
   PubMed Web of Science ®Google Scholar
• Andersen, M.H., Pedersen, L.O., Becker, J.C. and Straten, P.T. (2001) "Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients", Cancer Res., 61, 869 — 872.
   Google Scholar
• Pittet, Mi., Zippelius, A., Speiser, D.E., Assenmacher, M., Guillaume, P., Valmori, D., et al. (2001) "Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases", J. Immunol., 166, 7634–7640.
   PubMed Web of Science ®Google Scholar
• Krackhardt, AM., Harig, S., Witzens, M., Broderick, R., Barrett, P. and Gribben, J.G. (2002) "T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy", Blood, 100, 167 — 173.
   PubMed Web of Science ®Google Scholar
• Krackhardt, AM., Witzens, M., Harig, S., Hodi, F.S., Zauls, A.J., Chessia, M., et al. (2002) "Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX", Blood, 100, 2123–2131.
   Google Scholar
• Wang, Z., Zhang, Y., Liu, H., Salati, E., Chiriva-Internati, M. and Lim, S.H. (2003) "Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies", Blood, 101, 955–960.
   Google Scholar
• Schmidt, S.M., Schag, K., Muller, MR., Week, MM., Appel, S., Kanz, L., et al. (2003) "Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells", Blood, 102, 571 —576.
   Google Scholar